Nomura Asset Management Co. Ltd. Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Nomura Asset Management Co. Ltd. lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 2.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 68,017 shares of the biopharmaceutical company’s stock after purchasing an additional 1,804 shares during the quarter. […]

Related Keywords

Michaelw Bonney ,Sanfordc Bernstein ,Piper Sandler ,Quarter For Alnylam Pharmaceuticals ,Capital International Investors ,Nomura Asset Management Co ,Needham Company ,T Rowe Price Investment Management Inc ,Alnylam Pharmaceuticals Inc ,Alnylam Pharmaceuticals Stock Performance ,Alnylam Pharmaceuticals Profile ,Alnylam Pharmaceuticals ,Securities Exchange Commission ,News Ratings For Alnylam Pharmaceuticals Daily ,Vanguard Group Inc ,Nasdaq ,Blackrock Inc ,Nomura Asset Management ,Free Report ,Asset Management ,Rowe Price Investment Management ,Street Corp ,International Investors ,Get Free Report ,Director Michael ,Exchange Commission ,Visit Holdingschannel ,Alnylam Pharmaceuticals Daily ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,